Fig. 4: ARID1A mutations may compensate for mutant EGFR signaling by partially inducing an EGFR transcriptional program. | Nature Communications

Fig. 4: ARID1A mutations may compensate for mutant EGFR signaling by partially inducing an EGFR transcriptional program.

From: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Fig. 4

a Overview of genes with SV or copy-number alterations (CN) that are mutual exclusive (ME, purple) or co-occurring (CO, green) with ARID1A SVs based on the SELECT method32, in a CRC (n = 16,931) and lung cancer (n = 29,757) cohort from the FMI FoundationCORE database38. Known and likely oncogenic alterations in each gene were considered for the SELECT analysis. Asterisks indicate significant relationships (FDR < 0.1). b Overview of significant interactions with ARID1A SVs detected in lung cancer (top) and CRC (bottom), ranked by SELECT scores. c Mutation occurrences for 5980 patients with ARID1A and/or EGFR mutations in the FMI lung cancer cohort. d Overview of known and likely EGFR (top) and ARID1A (bottom) mutations in lung cancer patients. aa amino acid.

Back to article page